Alterations in brain transition metals in Huntington disease: An evolving and intricate story

Archives of Neurology

Volumn 69, Issue 7, 2012, Pages 887-893

  Rosas, H Diana ^a   Chen, Y Iris ^a   Doros, Gheorghe ^b   Salat, David H ^a   Chen, Nan Kuei ^c   Kwong, Ken K ^a   Bush, Ashley ^d   Fox, Jonathan ^a,e   Hersch, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; TRANSITION ELEMENT;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVATION; SEVERITY OF ILLNESS INDEX;

EID: 84863806222     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.2945     Document Type: Article

References (30)

1. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol. 1999;9(1):147-163. (Pubitemid 29056525)
2. Fox JH, Connor T, Stiles M, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem. 2011;286(20):18320-18330.
3. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res. 2007;32(10):1655-1664. (Pubitemid 47428858)
4. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand). 2000;46(4):821-833.
5. Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102(33):11840-11845. (Pubitemid 41170812)
6. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136-142.
7. Reber PJ, Wong EC, Buxton RB, Frank LR. Correction of off resonance-related distortion in echo-planar imaging using EPI-based field maps. Magn Reson Med. 1998;39(2):328-330. (Pubitemid 28099154)
8. Rauscher A, Sedlacik J, Barth M, Mentzel HJ, Reichenbach JR. Magnetic susceptibility- weighted MR phase imaging of the human brain. AJNR Am J Neuroradiol. 2005;26(4):736-742. (Pubitemid 43079761)
9. Young GS, Feng F, Shen H, Chen NK. Susceptibility-enhanced 3-Tesla T1- weighted spoiled gradient echo of the midbrain nuclei for guidance of deep brain stimulation implantation. Neurosurgery. 2009;65(4):809-815.
10. Chen NK, Oshio K, Panych LP. Application of k-space energy spectrum analysis to susceptibility field mapping and distortion correction in gradient-echo EPI. Neuroimage. 2006;31(2):609-622. (Pubitemid 43776658)
11. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004;14(7):721-730. (Pubitemid 38856947)
12. Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20(1):70-80. (Pubitemid 32293421)
13. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980. (Pubitemid 44183792)
14. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008;131(pt 4):1057-1068. (Pubitemid 351499426)
15. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-384. (Pubitemid 28237321)
16. Fox JH, Kama JA, Lieberman G, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS One. 2007;2(3):e334. http://www.ncbi.nlm. nih.gov/pmc/articles/PMC1828629/?tool=pubmed. Accessed January 6, 2012.
17. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:1096-1121.
18. R Web site. The R project for statistical computing. http://www.R- project.org. Accessed January 6, 2012.
19. Marder K, Zhao H, Myers RH, et al Huntington Study Group. Rate of functional decline in Huntington's disease. Neurology. 2000;54(2):452-458. (Pubitemid 30078083)
20. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR; International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-277. (Pubitemid 38443548)
21. Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci. 2008;1147:196-205.
22. Andreini C, Bertini I, Cavallaro G, Holliday GL, Thornton JM. Metal-MACiE: a database of metals involved in biological catalysis. Bioinformatics. 2009;25(16):2088-2089.
23. Deb S, Johnson EE, Robalinho-Teixeira RL, Wessling-Resnick M. Modulation of intracellular iron levels by oxidative stress implicates a novel role for iron in signal transduction. Biometals. 2009;22(5):855-862.
24. Benchoua A, Trioulier Y, Zala D, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17(4):1652-1663. (Pubitemid 44011583)
25. Mattson MP. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci. 2004;1012:37-50. (Pubitemid 38453514)
26. Myers RH, Vonsattel JP, Paskevich PA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol. 1991;50(6):729-742.
27. Gómez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001;49(1):29-34. (Pubitemid 32163003)
28. Dexter DT, Jenner P, Schapira AH, Marsden CD; The Royal Kings and Queens Parkinson's Disease Research Group. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol. 1992;32(suppl):S94-S100.
29. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem. 2001;79(6):1246-1249. (Pubitemid 34019802)
30. Hersch SM, Rosas HD. Biomarkers to enable the development of neuroprotective therapies for Huntington's disease. In: Lo DC, Hughes RE, eds. Neurobiology of Huntington's Disease Applications to Drug Discovery. New York, NY: CRC Press Taylor & Francis Group; 2010.